-
1
-
-
0001057794
-
A survey of neuroleptic-induced extrapyramidal reactions
-
Ayd FJJ: A survey of neuroleptic-induced extrapyramidal reactions. JAMA 1961; 175:1054-1061.
-
(1961)
JAMA
, vol.175
, pp. 1054-1061
-
-
Ayd, F.J.J.1
-
5
-
-
0020054615
-
Tardive dyskinesia: Prevalence and risk factors, 1959-1979
-
Kane JM, Smith JM: Tardive dyskinesia: Prevalence and risk factors, 1959-1979. Arch Gen Psychiatry 1982; 39:473-481.
-
(1982)
Arch Gen Psychiatry
, vol.39
, pp. 473-481
-
-
Kane, J.M.1
Smith, J.M.2
-
7
-
-
0026544764
-
Clinical efficacy of clozapine in treatment-refractory schizophrenia: An overview
-
Kane JM: Clinical efficacy of clozapine in treatment-refractory schizophrenia: An overview. Br J Psychiatry 1992; 160(suppl.17):41-45.
-
(1992)
Br J Psychiatry
, vol.160
, Issue.17 SUPPL.
, pp. 41-45
-
-
Kane, J.M.1
-
8
-
-
0026559173
-
Clozapine-associated agranulocytosis: Risk and aetiology
-
Krupp P, Barnes P: Clozapine-associated agranulocytosis: Risk and aetiology. Br J Psychiatry 1992; 160 (suppl. 17):38-40.
-
(1992)
Br J Psychiatry
, vol.160
, Issue.17 SUPPL.
, pp. 38-40
-
-
Krupp, P.1
Barnes, P.2
-
9
-
-
0034095251
-
Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol
-
The Canadian Collaborative Group for research in schizophrenia
-
Purdon SE, Jones BD, Stip E, Labelle A, Addington D, David SR, Brier A, Tollefson GD. Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. The Canadian Collaborative Group for research in schizophrenia. Archives of General Psychiatry 2000; 57:249-258.
-
(2000)
Archives of General Psychiatry
, vol.57
, pp. 249-258
-
-
Purdon, S.E.1
Jones, B.D.2
Stip, E.3
Labelle, A.4
Addington, D.5
David, S.R.6
Brier, A.7
Tollefson, G.D.8
-
10
-
-
0031963973
-
Antipsychotic properties of the partial dopamine agonist (-)-3(3-hydroxy-phenyl)-N-n-propylpiperidine (preclamol) in schizophrenia
-
Lahti AC, Weiler MA, Corey PK, et al. Antipsychotic properties of the partial dopamine agonist (-)-3(3-hydroxy-phenyl)-N-n-propylpiperidine (preclamol) in schizophrenia. Biol Psychiatry 1998; 43:2-11.
-
(1998)
Biol Psychiatry
, vol.43
, pp. 2-11
-
-
Lahti, A.C.1
Weiler, M.A.2
Corey, P.K.3
-
11
-
-
0031901331
-
Initial safety, tolerability, pharmacodynamics, and pharmacokinetics of CI-1007 in patients with schizophrenia
-
Sramek JJ, Eldon MA, Posvar E, et al. Initial safety, tolerability, pharmacodynamics, and pharmacokinetics of CI-1007 in patients with schizophrenia. Psychopharmacol Bull 1998; 34:93-99.
-
(1998)
Psychopharmacol Bull
, vol.34
, pp. 93-99
-
-
Sramek, J.J.1
Eldon, M.A.2
Posvar, E.3
-
12
-
-
0036089687
-
Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors
-
Burris KD, Molski TF, Xu C, et al. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther 2002; 302:381-389.
-
(2002)
J Pharmacol Exp Ther
, vol.302
, pp. 381-389
-
-
Burris, K.D.1
Molski, T.F.2
Xu, C.3
-
13
-
-
0037177358
-
The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor
-
Jordan S, Koprivica V, Chen R, Tottori K, Kikuchi T, Altar CA. The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor. Eur J Pharmacol 2002; 441:137-140.
-
(2002)
Eur J Pharmacol
, vol.441
, pp. 137-140
-
-
Jordan, S.1
Koprivica, V.2
Chen, R.3
Tottori, K.4
Kikuchi, T.5
Altar, C.A.6
-
14
-
-
0000671519
-
Aripiprazole: A dopamine-serotonin system stabilizer
-
McQuade RD, Burris KD, Jordan S, Tottori K, Kurahashi N, Kikuchi T. Aripiprazole: A dopamine-serotonin system stabilizer. Int J Neuropsychopharmacol 2002; 5(Suppl 1):S176.
-
(2002)
Int J Neuropsychopharmacol
, vol.5
, Issue.1 SUPPL.
-
-
McQuade, R.D.1
Burris, K.D.2
Jordan, S.3
Tottori, K.4
Kurahashi, N.5
Kikuchi, T.6
-
15
-
-
4644284333
-
-
Bristol-Myers Squibb Company, Princeton, New Jersey; November
-
Abilify™ prescribing information. Bristol-Myers Squibb Company, Princeton, New Jersey; November 2002.
-
(2002)
Abilify™ Prescribing Information
-
-
-
17
-
-
0033151286
-
Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes
-
Lawler CP, Prioleau C, Lewis MM, et al. Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes. Neuropsychopharmacol 1999; 20:612-627.
-
(1999)
Neuropsychopharmacol
, vol.20
, pp. 612-627
-
-
Lawler, C.P.1
Prioleau, C.2
Lewis, M.M.3
-
18
-
-
0034826997
-
Strategy for modulation of central dopamine transmission based on partial agonist concept in schizophrenia
-
Inoue A, Nakata Y. Strategy for modulation of central dopamine transmission based on partial agonist concept in schizophrenia. Jpn J Pharmacol 2001; 86:376-380.
-
(2001)
Jpn J Pharmacol
, vol.86
, pp. 376-380
-
-
Inoue, A.1
Nakata, Y.2
-
19
-
-
10744232425
-
Mechanism of action of new antipsychotic medications
-
Grunder G, Carlsson A, Wong D. Mechanism of action of new antipsychotic medications. Arch Gen Psychiatry 2003; 60:974-977.
-
(2003)
Arch Gen Psychiatry
, vol.60
, pp. 974-977
-
-
Grunder, G.1
Carlsson, A.2
Wong, D.3
-
21
-
-
84862424816
-
IA partial agonist
-
San Francisco, CA; May 17-22
-
IA partial agonist. Presented at the 2003 APA Annual Meeting, San Francisco, CA; May 17-22, 2003.
-
(2003)
2003 APA Annual Meeting
-
-
Jordan, S.1
Tadori, Y.2
McQuade, R.3
Yocca, F.4
Kostic, D.5
Kikuchi, T.6
-
22
-
-
0000649072
-
Meta-analysis of prolactin effects with aripiprazole
-
Carson WH, Saha AR, Iwamoto T, Lin C, Kujawa MJ. Meta-analysis of prolactin effects with aripiprazole. Int J Neuropsychopharmacol 2002b; 5(Suppl 1):S186.
-
(2002)
Int J Neuropsychopharmacol
, vol.5
, Issue.1 SUPPL.
-
-
Carson, W.H.1
Saha, A.R.2
Iwamoto, T.3
Lin, C.4
Kujawa, M.J.5
-
23
-
-
1442277874
-
Effects of renal and hepatic impairment on the pharmacokinetics of aripiprazole
-
May 17-22, San Francisco, CA
-
Bramer S, Shoaf S, Salazar DE, Mallikaarjun S. Effects of renal and hepatic impairment on the pharmacokinetics of aripiprazole. Presented at the 2003 APA Annual Meeting, May 17-22, 2003; San Francisco, CA.
-
(2003)
2003 APA Annual Meeting
-
-
Bramer, S.1
Shoaf, S.2
Salazar, D.E.3
Mallikaarjun, S.4
-
24
-
-
0000649067
-
Neurocognitive effects of aripiprazole versus olanzapine in stable psychosis
-
Cornblatt B, Kern RS, Carson WH, Ali MW, Luo X, Green M. Neurocognitive effects of aripiprazole versus olanzapine in stable psychosis. Int J Neuropsychopharmacol 2002; 5(Suppl 1):S185.
-
(2002)
Int J Neuropsychopharmacol
, vol.5
, Issue.1 SUPPL.
-
-
Cornblatt, B.1
Kern, R.S.2
Carson, W.H.3
Ali, M.W.4
Luo, X.5
Green, M.6
-
25
-
-
0038488945
-
Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder
-
Potkin SG, Saha AR, Kujawa MJ, Carson WH, Ali M, Stock E, Stringfellow J, Ingenito G, Marder SR. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 2003; 60:681-690.
-
(2003)
Arch Gen Psychiatry
, vol.60
, pp. 681-690
-
-
Potkin, S.G.1
Saha, A.R.2
Kujawa, M.J.3
Carson, W.H.4
Ali, M.5
Stock, E.6
Stringfellow, J.7
Ingenito, G.8
Marder, S.R.9
-
26
-
-
0002050453
-
Aripiprazole, a novel antipsychotic: Overview of a phase II study result
-
Daniel DG, Saha AR, Ingenito G, Carson WH, Dunbar G. Aripiprazole, a novel antipsychotic: Overview of a phase II study result. Int J Neuropsychopharmacol 2000; 3(Suppl 1):S157.
-
(2000)
Int J Neuropsychopharmacol
, vol.3
, Issue.1 SUPPL.
-
-
Daniel, D.G.1
Saha, A.R.2
Ingenito, G.3
Carson, W.H.4
Dunbar, G.5
-
27
-
-
0036738786
-
Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder
-
Kane JM, Carson WH, Saha A, McQuade RD, Ingenito GG, Zimbroff DL, Ali MW. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 2002; 63:763-771.
-
(2002)
J Clin Psychiatry
, vol.63
, pp. 763-771
-
-
Kane, J.M.1
Carson, W.H.2
Saha, A.3
McQuade, R.D.4
Ingenito, G.G.5
Zimbroff, D.L.6
Ali, M.W.7
-
28
-
-
0001612909
-
Aripiprazole, a new atypical antipsychotic: Phase II clinical trial result
-
Petrie JL, Saha AR, McEvoy JP. Aripiprazole, a new atypical antipsychotic: phase II clinical trial result. Eur Neuropsychopharm 1997; 7(Suppl 2):S227.
-
(1997)
Eur Neuropsychopharm
, vol.7
, Issue.2 SUPPL.
-
-
Petrie, J.L.1
Saha, A.R.2
McEvoy, J.P.3
-
29
-
-
0005122819
-
Meta-analysis of the efficacy of aripiprazole in schizophrenia
-
Lieberman J, Carson WH, Saha AR, et al. Meta-analysis of the efficacy of aripiprazole in schizophrenia. Int J Neuropsychopharmacol 2002; 5(Suppl 1):S186.
-
(2002)
Int J Neuropsychopharmacol
, vol.5
, Issue.1 SUPPL.
-
-
Lieberman, J.1
Carson, W.H.2
Saha, A.R.3
-
30
-
-
0000374942
-
Aripiprazole vs placebo in the treatment of chronic schizophrenia
-
Carson WH, Pigott TA, Saha AR, et al. Aripiprazole vs placebo in the treatment of chronic schizophrenia. Int J Neuropsychopharmacol 2002a; 5(Suppl 1):S187.
-
(2002)
Int J Neuropsychopharmacol
, vol.5
, Issue.1 SUPPL.
-
-
Carson, W.H.1
Pigott, T.A.2
Saha, A.R.3
-
31
-
-
0000649073
-
Aripiprazole for long-term maintenance treatment of schizophrenia
-
Kujawa M, Saha AR, Ingenito GG, et al. Aripiprazole for long-term maintenance treatment of schizophrenia. Int J Neuropsychopharmacol 2002; 5(Suppl 1):S186.
-
(2002)
Int J Neuropsychopharmacol
, vol.5
, Issue.1 SUPPL.
-
-
Kujawa, M.1
Saha, A.R.2
Ingenito, G.G.3
-
32
-
-
1442277872
-
Aripiprazole vs perphenazine in treatment-resistant schizophrenia
-
May 17-22, San Francisco, CA
-
Kane J, Carson W, Kujawa M, et al. Aripiprazole vs perphenazine in treatment-resistant schizophrenia. Presented at the 2003 APA Annual Meeting, May 17-22, 2003; San Francisco, CA.
-
(2003)
2003 APA Annual Meeting
-
-
Kane, J.1
Carson, W.2
Kujawa, M.3
-
34
-
-
0038585981
-
A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania
-
Keck Jr. PE, Marcus R, Tourkodimitris S et al. A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. American Journal of Psychiatry 2003; 160:1651-1658.
-
(2003)
American Journal of Psychiatry
, vol.160
, pp. 1651-1658
-
-
Keck Jr., P.E.1
Marcus, R.2
Tourkodimitris, S.3
-
37
-
-
2042459957
-
Aripiprazole vs haloperidol for maintained treatment effect in acute mania
-
May 17-22, San Francisco, CA
-
Bourin M, Auby P, Swanink R, et al. Aripiprazole vs haloperidol for maintained treatment effect in acute mania. Presented at the 2003 APA Annual Meeting, May 17-22, 2003; San Francisco, CA.
-
(2003)
2003 APA Annual Meeting
-
-
Bourin, M.1
Auby, P.2
Swanink, R.3
-
38
-
-
4644272448
-
Long-term effects of aripiprazole on the negative symptoms of schizophrenia
-
May 17-22, San Francisco, CA
-
Manos G, McQuade R, Stock E, et al. Long-term effects of aripiprazole on the negative symptoms of schizophrenia. Presented at the 2003 APA Annual Meeting, May 17-22, 2003; San Francisco, CA.
-
(2003)
2003 APA Annual Meeting
-
-
Manos, G.1
McQuade, R.2
Stock, E.3
-
40
-
-
0000649072
-
Meta-analysis of weight effects with aripiprazole
-
Jody D, Saha AR, Iwamoto T, et al. Meta-analysis of weight effects with aripiprazole. Int J Neuropsychopharmacol 2002b; 5(Suppl 1):S186.
-
(2002)
Int J Neuropsychopharmacol
, vol.5
, Issue.1 SUPPL.
-
-
Jody, D.1
Saha, A.R.2
Iwamoto, T.3
-
41
-
-
34447514978
-
Glycemic control and plasma lipids in long-term treatment with aripiprazole
-
May 17-22, San Francisco, CA
-
Marder SR, Jody D, Kaplita S, et al. Glycemic control and plasma lipids in long-term treatment with aripiprazole. Presented at the 2003 APA Annual Meeting, May 17-22, 2003; San Francisco, CA.
-
(2003)
2003 APA Annual Meeting
-
-
Marder, S.R.1
Jody, D.2
Kaplita, S.3
-
42
-
-
1442302481
-
Aripiprazole is not associated with increased diabetes risk: A long-term model
-
May 17-22, San Francisco, CA
-
Weiden P, Waldeck R, Tafesse E, Cislo P, L'Italien G, Carson W. Aripiprazole is not associated with increased diabetes risk: A long-term model. Presented at the 2003 APA Annual Meeting, May 17-22, 2003; San Francisco, CA.
-
(2003)
2003 APA Annual Meeting
-
-
Weiden, P.1
Waldeck, R.2
Tafesse, E.3
Cislo, P.4
L'Italien, G.5
Carson, W.6
-
43
-
-
1442302479
-
Metabolic syndrome comparison between olanzapine, aripiprazole, and placebo
-
May 17-22, San Francisco, CA
-
Casey D, L'Italien GL, Waldeck R, Cislo P, Carson W. Metabolic syndrome comparison between olanzapine, aripiprazole, and placebo. Presented at the 2003 APA Annual Meeting, May 17-22, 2003; San Francisco, CA.
-
(2003)
2003 APA Annual Meeting
-
-
Casey, D.1
L'Italien, G.L.2
Waldeck, R.3
Cislo, P.4
Carson, W.5
-
44
-
-
0035897696
-
Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)
-
Grundy SM, Decker D, Clark LT, et al. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285:2486-2497.
-
(2001)
JAMA
, vol.285
, pp. 2486-2497
-
-
Grundy, S.M.1
Decker, D.2
Clark, L.T.3
-
45
-
-
0000649068
-
Safety and tolerability meta-analysis of aripiprazole in schizophrenia
-
Stock E, Marder SR, Saha AR, et al. Safety and tolerability meta-analysis of aripiprazole in schizophrenia. Int J Neuropsychopharmacol 2002a; 5(Suppl 1):S186.
-
(2002)
Int J Neuropsychopharmacol
, vol.5
, Issue.1 SUPPL.
-
-
Stock, E.1
Marder, S.R.2
Saha, A.R.3
-
47
-
-
0021346160
-
Orthostatic Hypotension II. Clinical diagnosis, testing, and treatment
-
Schatz IJ: Orthostatic Hypotension II. Clinical diagnosis, testing, and treatment. Arch Intern Med 1984; 144:1037-1041.
-
(1984)
Arch Intern Med
, vol.144
, pp. 1037-1041
-
-
Schatz, I.J.1
-
48
-
-
0023119548
-
Management of anti-depressant-induced side effects. A practical guide for the clinician
-
Pollack MH, Rosenbaum JF: Management of anti-depressant-induced side effects. A practical guide for the clinician. J Clinical Psychiatry 1987; 48:3-8.
-
(1987)
J Clinical Psychiatry
, vol.48
, pp. 3-8
-
-
Pollack, M.H.1
Rosenbaum, J.F.2
-
49
-
-
4644357965
-
Aripiprazole treatment of institutionalized patients with psychosis of Alzheimer's dementia
-
February 21-24, Baltimore, MD
-
Streim JE, McQuade RD, Stock E et al. Aripiprazole treatment of institutionalized patients with psychosis of Alzheimer's dementia. Presented at 17 Annual meeting of the American Association of Geriatric Psychiatry, February 21-24, 2004; Baltimore, MD.
-
(2004)
17 Annual Meeting of the American Association of Geriatric Psychiatry
-
-
Streim, J.E.1
McQuade, R.D.2
Stock, E.3
-
50
-
-
4644346619
-
Safety and tolerability of aripiprazole in elderly patients with psychosis of Alzheimer's dementia: A pooled analysis
-
February 21-24, Baltimore, MD
-
Kujawa MJ and Bristol Meyers Squibb. Safety and tolerability of aripiprazole in elderly patients with psychosis of Alzheimer's dementia: A pooled analysis. Presented at 17 Annual meeting of the American Association of Geriatric Psychiatry, February 21-24, 2004; Baltimore, MD.
-
(2004)
17 Annual Meeting of the American Association of Geriatric Psychiatry
-
-
Kujawa, M.J.1
|